TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18634501

Group type: EXPERIMENTAL
Intervention: One intradermal injection of 0.1 ml (1 site) followed by two booster vaccinations of 0.1 ml (1 site) intradermally on days 0 and 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three intradermal injections within one week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three injections administered over 3-4 weeks with two booster vaccinations on days 0 and 3 one year later
Number of subjects: 0
Study: 16060244

Group type: EXPERIMENTAL
Intervention: Surgical treatment (craniotomy or endovascular coil embolization)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Natural course observation (no surgical treatment)
Number of subjects: 615
Study: 12370564

Group type: EXPERIMENTAL
Intervention: Rehydration after heat exposure
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rehydration after exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: No rehydration after heat exposure
Number of subjects: 8

Group type: COMPARATOR
Intervention: No rehydration after exercise
Number of subjects: 8
Study: 10559092

Group type: EXPERIMENTAL
Intervention: TAA HFA (150, 300, or 600 microg/d)
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: TAA P‐12 (150, 300, or 600 microg/d)
Number of subjects: 514

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514
Study: 9156925

Group type: EXPERIMENTAL
Intervention: Atrial signal‐averaged electrocardiogram (ALP) recording using HIPEC‐200HA in patients with PAF during IHD.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Atrial signal‐averaged electrocardiogram (ALP) recording using HIPEC‐200HA in healthy subjects.
Number of subjects: 75
Study: 1770066

Group type: EXPERIMENTAL
Intervention: Urokinase with dipyridamole or dilazep dihydrochloride
Number of subjects: 29

Group type: COMPARATOR
Intervention: Dipyridamole alone
Number of subjects: 29
Study: 6181965

Group type: EXPERIMENTAL
Intervention: 5 sec standard interval (SI) followed by a 3 sec SI-TI delay and then by a 4.5, 5.0 or 5.5 sec test interval (TI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 sec pre-response interval (PRI) succeeding to TI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 or 8 sec TIs randomly presented in each trial
Number of subjects: 0
Study: 31256356

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Adjustable gastric banding (AGB)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Medical weight loss (MWL)
Number of subjects: 12
Study: 30008589

Group type: EXPERIMENTAL
Intervention: LdT (telbivudine) treatment
Number of subjects: 112

Group type: COMPARATOR
Intervention: Observation group (no antiviral therapy)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study: 27779639

Group type: EXPERIMENTAL
Intervention: Light exercise program (2-hour education session, five weekly 90-minute exercise training sessions, and home-based self-managed exercise program)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Light exercise program
Number of subjects: 353

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 353
Study: 25532087

Group type: EXPERIMENTAL
Intervention: PCEA (bolus - 5 ml, lockout interval - 15 minutes, basal rate - 0 ml) with bupivacaine 0.08% and fentanyl 2 µg/ml
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: PCEA
Number of subjects: 51

Group type: COMPARATOR
Intervention: CEA (10 ml/h) with bupivacaine 0.08% and fentanyl 2 µg/ml
Number of subjects: 51

Group type: COMPARATOR
Intervention: CEA
Number of subjects: 51
Study: 22227853

Group type: EXPERIMENTAL
Intervention: Salivary lactate (sLac)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salivary alpha-amylase (sAA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salivary chromogranin A (sCgA)
Number of subjects: 12
Study: 19584823

Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG, thymoglobuline) on day+7, n=84
Number of subjects: 170

Group type: COMPARATOR
Intervention: No treatment (controls), n=86
Number of subjects: 170
Study: 17081656

Group type: EXPERIMENTAL
Intervention: 6 isoenergetic meals fed hourly
Number of subjects: 16

Group type: COMPARATOR
Intervention: 2 isoenergetic meals 3 h apart
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both feeding patterns
Number of subjects: 16
Study: 15604943

Group type: EXPERIMENTAL
Intervention: Delayed imaging with tetrofosmin
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Delayed imaging with sestamibi
Number of subjects: 131

Group type: COMPARATOR
Intervention: Administration of milk
Number of subjects: 131

Group type: COMPARATOR
Intervention: Administration of milk plus water
Number of subjects: 131

Group type: COMPARATOR
Intervention: Comparison between tetrofosmin and sestamibi
Number of subjects: 131
Study: 12026752

Group type: EXPERIMENTAL
Intervention: Green paper questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pink paper questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blue paper questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yellow paper questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colored paper (any color)
Number of subjects: 0
Study: 10327033

Group type: EXPERIMENTAL
Intervention: Tomudex (raltitrexed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) plus leucovorin (LV)
Number of subjects: 0
Study: 8617079

Group type: EXPERIMENTAL
Intervention: HFA 134a salbutamol sulfate
Number of subjects: 24

Group type: COMPARATOR
Intervention: CFC 11/12 salbutamol
Number of subjects: 24
Study: 1782715

Group type: EXPERIMENTAL
Intervention: Topical antibiotic/steroid mixture with alternate day dressings
Number of subjects: 10

Group type: COMPARATOR
Intervention: Topical antibiotic/steroid mixture with sump filling
Number of subjects: 10
Study: 6168426

Group type: EXPERIMENTAL
Intervention: MOPP (nitrogen mustard, vincristine, procarbazine and prednisone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MOP (the same combination without prednisone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: B‐MOPP (MOPP plus bleomycin at low dosage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MOPP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LOPP (chlorambucil substituted for nitrogen mustard)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CVB combination (CCNU, vinblastine and bleomycin)
Number of subjects: 0
Study: 31483962

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 798

Group type: COMPARATOR
Intervention: Foam sclerotherapy
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness model favoring laser ablation
Number of subjects: 798
Study: 28631408

Group type: EXPERIMENTAL
Intervention: Hydrophilic SAE (modified SAE)
Number of subjects: 21

Group type: COMPARATOR
Intervention: SAE (control group)
Number of subjects: 21
Study: 26062633

Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI) at 10°C for 10 minutes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Active Recovery (ACT) - low-intensity cycling for 10 minutes
Number of subjects: 10
Study: 23722897

Group type: EXPERIMENTAL
Intervention: Intravoxel incoherent motion (IVIM) MR imaging for nasopharyngeal carcinoma (NPC)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Intravoxel incoherent motion (IVIM) MR imaging for post‐chemoradiation fibrosis
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Cut-off values for IVIM parameters
Number of subjects: 83
Study: 21338797

Group type: EXPERIMENTAL
Intervention: Exposed calves bedded with sand previously positive for M. bovis (n=6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Unexposed controls bedded with control sand (n=6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exposed group sand
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Probability of mycoplasma detection in exposed calves
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 12
Study: 19034466

Group type: EXPERIMENTAL
Intervention: Anteromedial (A-M) trans-tibia approach
Number of subjects: 55

Group type: COMPARATOR
Intervention: Anterolateral (A-L) trans-tibia approach
Number of subjects: 55
Study: 18089334

Group type: EXPERIMENTAL
Intervention: Valganciclovir oral solution (900 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Valganciclovir tablets (900 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Valganciclovir oral solution
Number of subjects: 23

Group type: COMPARATOR
Intervention: Valganciclovir tablets
Number of subjects: 23

Group type: COMPARATOR
Intervention: Valganciclovir oral solution vs tablets
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Valganciclovir oral solution and tablets
Number of subjects: 23
Study: 10990571

Group type: EXPERIMENTAL
Intervention: Vernix caseosa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eucerin(R)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aquaphor(R)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Petrolatum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control skin
Number of subjects: 0
Study: 8791950

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.d., clarithromycin 250 mg b.d., metronidazole 400 mg b.d. (cohort A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg b.d., clarithromycin 250 mg b.d., tetracycline 300 mg b.d. (cohort B)
Number of subjects: 120
Study: 1538013

Group type: EXPERIMENTAL
Intervention: Flushed venous sheath between each biopsy attempt
Number of subjects: 51

Group type: COMPARATOR
Intervention: Flushed venous sheath only at the time of initial placement
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: More than six biopsy attempts
Number of subjects: 51
Study: 6209488

Group type: EXPERIMENTAL
Intervention: Nicardipine 5 mg i.v.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nicardipine 10 mg i.v.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nicardipine 2.5 mg i.v. after beta-blockade with propranolol
Number of subjects: 19
Study: 31180258

Group type: EXPERIMENTAL
Intervention: FCL plus topical SC‐CM
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: FCL plus topical PRP
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: FCL/PRP and FCL/SC‐CM
Number of subjects: 33

Group type: COMPARATOR
Intervention: FCL only
Number of subjects: 33
Study: 31211326

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 454

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 454
Study: 29032362

Group type: EXPERIMENTAL
Intervention: Risk score based on non-ischaemia-related independent prognostic predictors
Number of subjects: 14279

Group type: EXPERIMENTAL
Intervention: Ischaemia at stress echocardiography
Number of subjects: 14279
Study: 27302306

Group type: EXPERIMENTAL
Intervention: Supportive-expressive discussion groups (12 weekly 90-min sessions)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 81
Study: 25419597

Group type: EXPERIMENTAL
Intervention: Low-dose oral, delayed-release mesalamine (27-71 mg · g(‐1) · day(‐1))
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: High-dose oral, delayed-release mesalamine (53-118 mg · g(‐1) · day(‐1))
Number of subjects: 81

Group type: COMPARATOR
Intervention: Low-dose oral, delayed-release mesalamine
Number of subjects: 81

Group type: COMPARATOR
Intervention: High-dose oral, delayed-release mesalamine
Number of subjects: 81
Study: 22449453

Group type: EXPERIMENTAL
Intervention: Artificial urinary sphincter (AUS), AMS-800 placement
Number of subjects: 12
Study: 21314086

Group type: EXPERIMENTAL
Intervention: LED LCU (LEDMAX 4, Hilux, Kulzer comp.) for 10 seconds
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: LED LCU (LEDMAX 4, Hilux, Kulzer comp.) for 20 seconds
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: LED LCU (LEDMAX 4, Hilux, Kulzer comp.) for 40 seconds
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional halogen-based LCU (Hilux unit, Heraeus Kulzer comp.) for 40 seconds
Number of subjects: 120
Study: 18379511

Group type: EXPERIMENTAL
Intervention: Hydroxyzine (atarax) as a substitutive therapy after immediate withdrawal of BDT
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo therapy during continuous withdrawal of BDT over 14 days
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Hydroxyzine (atarax)
Number of subjects: 59
Study: 16087407

Group type: EXPERIMENTAL
Intervention: Structured nurse-led intervention program (1-day group education followed by extended nurse follow-up and counseling)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Structured nurse-led intervention program
Number of subjects: 114
Study: 12161494

Group type: EXPERIMENTAL
Intervention: CRH stimulation test
Number of subjects: 11
Study: 10385768

Group type: EXPERIMENTAL
Intervention: Intravenous continuous dobutamine
Number of subjects: 471

Group type: COMPARATOR
Intervention: No dobutamine
Number of subjects: 471
Study: 7475768

Group type: EXPERIMENTAL
Intervention: Screening for H pylori serology
Number of subjects: 183

Group type: COMPARATOR
Intervention: Non-endoscoped screen-negative patients
Number of subjects: 183
Study: 2275270

Group type: EXPERIMENTAL
Intervention: Benzonal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 0
Study: 31682891

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 18
Study: 31452486

Group type: EXPERIMENTAL
Intervention: Individual format of cognitive-behavioral intervention
Number of subjects: 360

Group type: COMPARATOR
Intervention: Group format of cognitive-behavioral intervention
Number of subjects: 360
Study: 29129192

Group type: EXPERIMENTAL
Intervention: MI+HealthCall-S
Number of subjects: 42

Group type: COMPARATOR
Intervention: MI-only
Number of subjects: 42
Study: 26293185

Group type: EXPERIMENTAL
Intervention: Degradable PDLLA‐membrane for sinus membrane elevation
Number of subjects: 5

Group type: COMPARATOR
Intervention: Mixture of autogenous and xenogenous bone for conventional sinus floor augmentation
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Both techniques (experimental and control)
Number of subjects: 5
Study: 23235199

Group type: EXPERIMENTAL
Intervention: Emulsified fat
Number of subjects: 18
Study: 21797917

Group type: EXPERIMENTAL
Intervention: rhGDF‐5/β‐TCP with a 3‐month healing period
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rhGDF‐5/β‐TCP with a 4‐month healing period
Number of subjects: 30

Group type: COMPARATOR
Intervention: β‐TCP and autogenous bone (β‐TCP/AB) with a 4‐month healing period
Number of subjects: 30
Study: 20394247

Group type: EXPERIMENTAL
Intervention: remifentanil 1 microg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: saline 3 ml
Number of subjects: 60
Study: 17217362

Group type: EXPERIMENTAL
Intervention: Antiatherogenic diet low in saturated fat and cholesterol from gestational week 17‐20 to birth
Number of subjects: 290

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 290
Study: 15961699

Group type: EXPERIMENTAL
Intervention: Physiological (PHYS) noninvasive Pressure Support Ventilation (nPSV)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Usual (US) noninvasive Pressure Support Ventilation (nPSV)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: nPSV (both settings)
Number of subjects: 9
Study: 12190807

Group type: EXPERIMENTAL
Intervention: Tramadol plus magnesium (TM)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Tramadol plus ketamine (TK)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Tramadol alone (T)
Number of subjects: 66
Study: 7651682

Group type: EXPERIMENTAL
Intervention: Alkalinized anesthetic solution
Number of subjects: 21

Group type: COMPARATOR
Intervention: Fixed-volume alkalinization
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nadbath injection
Number of subjects: 21
Study: 2523264

Group type: EXPERIMENTAL
Intervention: Dilevalol (200 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 349379

Group type: EXPERIMENTAL
Intervention: Concurrent quality assurance (CQA)
Number of subjects: 5604

Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 5604
Study: 31712214

Group type: EXPERIMENTAL
Intervention: RV521 350 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: RV521 200 mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 31690775

Group type: EXPERIMENTAL
Intervention: Genetically instrumented blood lead
Number of subjects: 361194
Study: 28727702

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of triamcinolone and lidocaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard therapy (oral antivirals and analgesics)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 26557618

Group type: EXPERIMENTAL
Intervention: Diode laser technique
Number of subjects: 70

Group type: COMPARATOR
Intervention: Scalpel technique
Number of subjects: 70
Study: 23698171

Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART) by dentists
Number of subjects: 1629

Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART) by auxiliaries
Number of subjects: 1629

Group type: COMPARATOR
Intervention: Amalgam by dentists
Number of subjects: 1629

Group type: EXPERIMENTAL
Intervention: Cost of ART
Number of subjects: 1629
Study: 21744945

Group type: EXPERIMENTAL
Intervention: Online CBT (NET)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Clinic-based CBT (CLIN)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Wait list control (WLC)
Number of subjects: 115
Study: 19188683

Group type: EXPERIMENTAL
Intervention: Mitochondrial-targeted antioxidant treatment in rats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically engineered overexpression of catalase in mitochondria of muscle in mice
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 0
Study: 17211305

Group type: EXPERIMENTAL
Intervention: 9 mg of isobaric bupivacaine with 20 microgr fentanyl
Number of subjects: 40

Group type: COMPARATOR
Intervention: 13.5 mg of standardized isobaric 0.5% bupivacaine
Number of subjects: 40
Study: 12776641

Group type: COMPARATOR
Intervention: Intravenous ondansetron (4 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Inhaled isopropyl alcohol (70%)
Number of subjects: 100
Study: 10671913

Group type: EXPERIMENTAL
Intervention: Health authority/pharmaceutical company collaborative intervention
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 140
Study: 9483987

Group type: EXPERIMENTAL
Intervention: Naclof (sodium diclofenac) eye drops
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no Naclof)
Number of subjects: 40
Study: 8404196

Group type: EXPERIMENTAL
Intervention: High-frequency ventilation (HFV)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation (SIMV)
Number of subjects: 12
Study: 3007219

Group type: EXPERIMENTAL
Intervention: Surgical treatment (open biopsy, resection, excision)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Incomplete removal of the tumor (surgery)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Overall surgical treatment
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Post-operative radiotherapy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Post-operative chemotherapy
Number of subjects: 43
Study: 31939316

Group type: EXPERIMENTAL
Intervention: Oral estradiol (E2)
Number of subjects: 1512

Group type: EXPERIMENTAL
Intervention: Serum E2 levels
Number of subjects: 1512
Study: 29885694

Group type: EXPERIMENTAL
Intervention: MVD with concomitant non-IRA CTO (n = 74)
Number of subjects: 791

Group type: COMPARATOR
Intervention: MVD without CTO (n = 372)
Number of subjects: 791

Group type: COMPARATOR
Intervention: SVD (n = 345)
Number of subjects: 791
Study: 26287652

Group type: EXPERIMENTAL
Intervention: Home-based treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Hospital-based treatment
Number of subjects: 18
Study: 24824014

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acid (MUFA) meal (macadamia nut oil)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 34
Study: 23394509

Group type: EXPERIMENTAL
Intervention: High-dose inhaled corticosteroids (ICSs) at doses of two, four, or eight times their maintenance ICS dose for 12 days
Number of subjects: 197

Group type: COMPARATOR
Intervention: Doubling the maintenance dose of ICS
Number of subjects: 197
Study: 20881507

Group type: EXPERIMENTAL
Intervention: Strength training at 80% of 1-repetition maximum (1RM) for 4 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 23
Study: 18395165

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Statin-fibrate therapy (control)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 27
Study: 16371630

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 1441
Study: 12645393

Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg/die for six months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 9583927

Group type: EXPERIMENTAL
Intervention: Aminosidine 12 mg/kg/day for 21 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aminosidine 16 mg/kg/day for 21 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aminosidine 20 mg/kg/day for 21 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sodium stibogluconate 20 mg/kg/day for 30 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aminosidine (16 and 20 mg/kg/day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 120
Study: 7712676

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2559525

Group type: EXPERIMENTAL
Intervention: Bone marrow biopsy (BMB)
Number of subjects: 71
Study: 413794

Group type: EXPERIMENTAL
Intervention: Gnotobiotic care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28598897

Group type: EXPERIMENTAL
Intervention: Global Trigger Tool (GTT) methodology implementation with continuous training and specific review rules.
Number of subjects: 1320

Group type: COMPARATOR
Intervention: First round interrater reliability assessment before intervention.
Number of subjects: 1320